In vivo modulation of lymphokine-activated killer cell activity by cell wall components of Candida albicans.
We have previously reported that inoculating CD2F1 mice intraperitoneally with five doses of 2 x 10(7) inactivated Candida albicans (CA) cells was associated with the induction of lymphokine-activated killer (LAK)-like effectors. In this study we investigated the ability of some purified cell wall components of CA (CA-CW) to induce LAK-like cells in vivo. Multiple administrations of glucan ghost (GG), a mannoprotein mixture (MP) and a low-protein mannan fraction (M) at variance with whole CA did not induce LAK-like cells in the peritoneal cavity. However, the broad-spectrum antitumor cytotoxicity induced by CA could be recalled to a high level by a booster dose of MP and M, but not GG, given up to 70 days after the multiple CA-treatment. This induced cytotoxicity was maximum when the booster was given on Day +14 after CA-treatment and minimum on Day +70. In CA-treated mice, inoculated on Day +30 with CA or MP, LAK-like cytotoxicity was already significantly increased 4 hr after the booster, but the maximum value was reached at 24 hr. Anti-mannan antibodies did not interfere with LAK-like cells induction by CA because splenectomy before CA-treatment or passive administration of anti-mannan antibodies had no effect on the rapid activation of cytotoxicity by CA or a booster dose of MP. Administration of recombinant human interleukin-2 (rhIL-2) to CA-treated mice induced a higher level of NK activity than that induced by the same dose in untreated control mice, but did not activate LAK-like effectors. The results indicate that LAK-like effectors are easily generated in the peritoneal cavity by a booster with a defined antigenic constituent of CA cell wall for a long period in CA-sensitized mice.
Scaringi
L
L
Institute of General Pathology, University of Perugia, Italy.
Rosati
E
E
Cornacchione
P
P
Rossi
R
R
Marconi
P
P
D000818:Animals; D000942:Antigens, Bacterial / Q000008:administration & dosage* / Q000276:immunology; D002176:Candida albicans / Q000276:immunology*; D002460:Cell Line / Q000187:drug effects; D002473:Cell Wall / Q000276:immunology*; D004305:Dose-Response Relationship, Drug; D005260:Female; D005936:Glucans / Q000276:immunology / Q000494:pharmacology; D007376:Interleukin-2 / Q000494:pharmacology*; D015979:Killer Cells, Lymphokine-Activated / Q000276:immunology*; D008297:Male; D008351:Mannans / Q000276:immunology / Q000494:pharmacology; D051379:Mice; D011994:Recombinant Proteins / Q000494:pharmacology
D000942:Antigens, Bacterial; D005936:Glucans; D007376:Interleukin-2; D008351:Mannans; D011994:Recombinant Proteins